IDH1 and glioma: Wu constructed a six-gene signature that could classify IDH-mutant GBM patients into high or low risk of poor outcome using 33 samples from the Chinese Glioma Genome Atlas RNA-sequencing data and 21 cases from Chinese Glioma Genome Atlas microarray data (7).